Table 2 Characteristics of HER2 mutations in patients stratified according to the HER2 amplification status.

From: Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

Characteristics

No. of cases (%)

P

Total (n = 529a)

HER2 amplification-positive (n = 477)

HER2 amplification-negative (n = 52)

ERBB2 exon

    

 19

31 (5.9)

17 (3.6)

14 (26.9)

<0.001

 20

38 (7.2)

28 (5.9)

10 (19.2)

 21

27 (5.1)

25 (5.2)

2 (3.8)

 Other

433 (81.9)

407 (85.3)

26 (50.0)

Mutation site

    

 ECD

225 (42.5)

212 (44.4)

13 (25.0)

<0.001

 TKI

153 (28.9)

123 (25.8)

30 (57.7)

 Other

151 (28.5)

142 (29.8)

9 (17.3)

Variant classification

    

 Missense

488 (92.2)

443 (92.9)

45 (86.5)

<0.001

 Nonsense

19 (3.6)

19 (4.0)

0 (0.0)

 Frame shift

15 (2.8)

8 (1.7)

7 (13.5)

 Other

7 (1.3)

7 (1.5)

0 (0.0)

Variant type

    

 SNP

514 (97.2)

469 (98.3)

45 (86.5)

<0.001

 INS

6 (1.1)

2 (0.4)

4 (7.7)

 DEL

9 (1.7)

6 (1.3)

3 (5.8)

 VAF mean ± SD

2.1 ± 9.0

1.2 ± 7.0

10.2 ± 17.4

<0.001

Clonality status

    

 Clonal

24 (4.5)

15 (3.1)

9 (17.3)

<0.001

 Subclonal

505 (95.5)

462 (96.9)

43 (82.7)

Hotspot mutations

    

 p.V777L

13 (2.5)

9 (1.9)

4 (7.7)

<0.001

 p.D769Y/H

11 (2.1)

4 (0.8)

7 (13.5)

 p.L755S

10 (1.9)

7 (1.5)

3 (5.8)

 p.S310F/Y

9 (1.7)

4 (0.8)

5 (9.6)

 Other

486 (91.9)

453 (95.0)

33 (63.5)

  1. DEL deletion mutation, ECD extracellular domain, HER2 human epidermal growth factor receptor 2, INS insertion mutation, SNP single-nucleotide polymorphism, TKI tyrosine kinase domain, VAF variant allele frequency.
  2. aStatistical analysis based on the mutation number.